

## **Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)**

**Lund, Sweden, 18:00 CET 28 December 2018 - During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,795,917.**

### **About BONESUPPORT™**

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT® and CERAMENT® are registered trademarks

### **For more information contact:**

#### **BONESUPPORT AB**

Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46 (0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

#### **Citigate Dewe Rogerson**

Pip Batty, David Dible, Shabnam Bashir  
+44 (0)20 7282 1022  
[bonesupport@citigatedewerogerson.com](mailto:bonesupport@citigatedewerogerson.com)

The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on 28 December 2018.